Adenosine Receptor Antagonist 3（Cat No.:I044049）is a selective small-molecule inhibitor targeting adenosine receptors, particularly A2A and A2B subtypes, which play key roles in immunosuppression, inflammation, and tumor progression. By blocking these receptors, the antagonist enhances T-cell and natural killer (NK) cell activity, counteracts adenosine-mediated immune evasion, and promotes anti-tumor immune responses. It is especially valuable in cancer immunotherapy research and inflammatory disease models. Adenosine Receptor Antagonist 3 supports the development of combination strategies with checkpoint inhibitors and enables detailed study of purinergic signaling in immune regulation and tumor microenvironment modulation.